Ab1353-Hpr prevalence of Pain Medications Prescriptions in Patients With Ra

Abstract

BackgroundPain is often disabling and can reduce the quality of life of a patient. Pain medications are drugs commonly prescribed for a variety of conditions one of them rheumatoid arthritis. The common molecules prescribed are paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids.ObjectivesThe goal of this study was to analyze the prevalence of pain medication prescription in patients with Rheumatoid Arthritis in a specialized center in Colombia.MethodsWe collected data from the medical charts in a specialized RA center conducted during 5 years, we performed a descriptive analysis, we collected sociodemographic information, DAS28, and the prevalence of prescription of analgesic medications divided in three groups non-opioid analgesics, opioid analgesics and NSAIDS. We calculated means, and standard deviations for continuous variables and categorical variables were presented as rates. We evaluated the relationship between DAS28 and the usage of pain medications.ResultsWe reviewed the medical charts of 7076 patients diagnosed with rheumatoid arthritis, 82% were female and 17% were male. Median age was 60 years RIQ (51-69). The prevalence of usage of pain medications was 45%. Most of patients received paracetamol followed by a combination of paracetamol. See table 1. The prevalence of pain medications usage was not with associated disease activity.Pain medication n % Paracetamol240734Paracetamol + opioids74411NSAID631ConclusionAs other studies have shown the prevalence of pain medications in patients with RA is high. The most prescribed medication was paracetamol or opioids, coinciding with other studies (1). This descriptive study is useful for further studies to develop in Colombia and Latin America. Additionally, it is important to consider other alternative therapies in order to approach in painful condition like RA.Disclosure of Interests Wilberto Rivero: None declared, Diana Buitrago-Garcia: None declared, Pedro Santos-Moreno Grant/research support from: Dr Santos has received research grants from Janssen, Abbvie and UCB, Speakers bureau: Dr Santos has received speaker fees from Sanofi, Lilly, Bristol, Pfizer, Abbvie, Janssen and UCB, Fernando Rodriguez: None declared